Exogenous vasopressin dose-dependently modulates gastric microcirculatory oxygenation in dogs via V1A receptor

Truse, Richard; Grewe, Steven; Herminghaus, Anna; Schulz, Jan; Weber, Andreas P. M.; Mettler-Altmann, Tabea; Bauer, Inge; Picker, Olaf; Vollmer, Christian

doi:10.1186/s13054-019-2643-y

Critical Care

Table 1 Micro- and macrocirculatory variables

From: Exogenous vasopressin dose-dependently modulates gastric microcirculatory oxygenation in dogs via V1A receptor

Parameter	Treatment	Baseline, 0.5 h	± VB, 1.0 h	Dose 1, 1.5 h	Dose 2, 2.0 h	Dose 3, 2.5 h	Dose 4, 3.0 h
Gastric μvelo (aU)	C	20 ± 8	20 ± 6	20 ± 5	20 ± 5	18 ± 5	20 ± 6
	AVP	19 ± 5	22 ± 3	23 ± 4	22 ± 5	20 ± 5	17 ± 4
	VB	20 ± 5	23 ± 6	22 ± 5	22 ± 6	23 ± 8^#	22 ± 7
	AVP VB	20 ± 6	20 ± 2	23 ± 4	23 ± 5	21 ± 4	21 ± 3^§
Gastric rHb (aU)	C	60 ± 9	58 ± 11	57 ± 10	57 ± 12	57 ± 10	56 ± 14
	AVP	54 ± 15	57 ± 12	57 ± 12	59 ± 13	56 ± 11	47 ± 14^*#
	VB	58 ± 6	59 ± 10	55 ± 10	55 ± 10	54 ± 11	51 ± 10^*
	AVP VB	60 ± 13	60 ± 8	57 ± 8	59 ± 10	59 ± 13	57 ± 11^§
Oral μvelo (aU)	C	25 ± 10	24 ± 8	21 ± 7	22 ± 4	24 ± 10	21 ± 4
	AVP	22 ± 6	19 ± 3	23 ± 8	21 ± 5	19 ± 3	16 ± 2
	VB	26 ± 3	29 ± 9	25 ± 5	24 ± 5	24 ± 4	24 ± 3
	AVP VB	25 ± 7	25 ± 6	23 ± 5	25 ± 7	23 ± 3	26 ± 8
Oral rHb (aU)	C	94 ± 10	90 ± 8	87 ± 10^*	89 ± 6	88 ± 6	89 ± 6
	AVP	91 ± 3	88 ± 5	89 ± 6	89 ± 5	83 ± 5^*	72 ± 9^*#
	VB	94 ± 6	95 ± 9	91 ± 6	92 ± 7	91 ± 6	88 ± 8
	AVP VB	95 ± 7	93 ± 6	91 ± 7	92 ± 7	91 ± 8^§	94 ± 8^§
TVD (mm/mm²)	C	19 ± 1.6	19 ± 2.1	20 ± 1.5	20 ± 1.0	20 ± 1.5	20 ± 2.1
	AVP	21 ± 1.3	20 ± 1.3	20 ± 2.1	20 ± 1.2	20 ± 2.2	18 ± 2.7^*
	VB	20 ± 0.9	20 ± 1.9	19 ± 1.3^*	18 ± 1.3^*#	19 ± 1.6	20 ± 1.3
	AVP VB	19 ± 1.1	19 ± 1.2	19 ± 1.8	20 ± 2.3	19 ± 1.6	20 ± 1.2
PPV (%)	C	56 ± 8.9	49 ± 16.7	49 ± 19.2	53 ± 9.6	57 ± 8.8	56 ± 8.2
	AVP	61 ± 11.0	62 ± 8.0^#	60 ± 12.9	51 ± 8.1	43 ± 20.8	32 ± 14.6^*#
	VB	63 ± 5.9	52 ± 13.9	49 ± 17.8	52 ± 12.2	53 ± 12.6	54 ± 16.5
	AVP VB	59 ± 7.4	62 ± 9.5	49 ± 8.7	56 ± 8.5	53 ± 12.6	61 ± 14.7^§
SV (ml)	C	23 ± 3	23 ± 3	24 ± 3	23 ± 2	23 ± 3	23 ± 3
	AVP	23 ± 2	23 ± 2	23 ± 2	23 ± 2	22 ± 2	22 ± 2
	VB	24 ± 3	25 ± 4^#	24 ± 3	25 ± 4^#	26 ± 4^#	27 ± 4^*#
	AVP VB	24 ± 4	24 ± 4	26 ± 4^#§	26 ± 4^*#§	27 ± 4^*#§	29 ± 4^*#§
HR (1/min)	C	121 ± 8	121 ± 6	118 ± 8	119 ± 7	119 ± 6	118 ± 6^*
	AVP	120 ± 6	120 ± 7	120 ± 7	118 ± 6	116 ± 6^*	104 ± 10^*#
	VB	119 ± 4	120 ± 4	119 ± 4	117 ± 4	116 ± 5^*#	114 ± 6^*#
	AVP VB	122 ± 9	126 ± 6^*#§	120 ± 6	119 ± 7	118 ± 8^*	117 ± 9^*§
dPmax (mmHg/s)	C	437 ± 21	407 ± 30^*	403 ± 40^*	398 ± 37^*	390 ± 35^*	395 ± 52^*
	AVP	447 ± 27	422 ± 32	420 ± 51	415 ± 52^*	393 ± 59^*	353 ± 43^*#
	VB	425 ± 29	425 ± 43	425 ± 45	422 ± 52	428 ± 53^#	422 ± 53
	AVP VB	450 ± 51	450 ± 72^#	458 ± 56^#§	468 ± 56^#§	477 ± 74^#§	503 ± 96^*#§

Micro- and macrocirculatory variables of the different types of treatment—gastric and oral microcirculatory velocity (μvelo), relative hemoglobin amount (rHb), total vessel density (TVD), proportion of perfused vessels (PPV), stroke volume (SV), heart rate (HR), and maximum left ventricular contractility (dPmax). Data are presented as mean ± SD for n = 6 dogs
*p < 0.05 vs. baseline
^#p < 0.05 vs. control (C), 2-way ANOVA for repeated measurements followed by Dunnett’s post hoc test
^§p < 0.05 for AVP VB vs. AVP, 2-way ANOVA for repeated measurements followed by Bonferroni’s post hoc test

Back to article page

ISSN: 1364-8535

Contact us

Submission enquiries: journalsubmissions@springernature.com